Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 and ED95 of oliceridine fumarate to suppress bronchoscopy response under remimazolam sedation
ChiCTR2500114090Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oliceridine (2 arms), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: ED50 and ED95 of oliceridine fumarate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
oliceridine
Beyond the preview
Go deeper on ChiCTR2500114090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114090.